The Traderszone Network

Published in TZ Latest News 7 November, 2015 by The TZ Newswire Staff

Vertex Pharmaceuticals’ $2.6 Billion Bet on CRISPR

CRISPR-Cas9 gene editing may be a huge breakthrough, but the odds are long and the field is crowded.